TABLE 2

Published plasma pharmacokinetic parameters of BEL in humans after a single intravenous dose

Human Subjects with Cancer Type	Dosage of BEL	C_max (µM)	T_max (h)	t_1/2 (h)	AUC_(0–t) (µM/h)	Reference
Prostate adenocarcinoma, thymus, urothelial carcinoma, and uterine leiomyosarcoma	1000 mg/m²	131 ± 31.6	0.48	2.9 ± 4.51	86.8 ± 21.7 (0–24 h)	Bailey et al. (2016)
Uterine carcinosarcoma, urothelial bladder carcinoma, pancreatic adenocarcinoma, lung adenocarcinoma, gastroesophageal junction, and colorectal carcinoma	1500 mg	175.59 ± 41.46^{^a}	0.48	1.58	103.03 ± 19.41 (0–12 h)^{^a}	Calvo et al. (2016)
Hepatocellular carcinoma	900 mg/m²	98.34 ± 29.66^{^a}	0.42	4.07 ± 0.39	69.94 ± 17.22 (0–24 h)^{^a}	Yeo et al. (2012)
	1200 mg/m²	153.29 ± 50.33^{^a}	0.42	4.14 ± 0.42	122.46 ± 37 (0–24 h)^{^a}	Yeo et al. (2012)
	1400 mg/m²	182.92 ± 56.11^{^a}	0.45	3.49 ± 0.73	149.21 ± 44.11 (0–24 h)^{^a}	Yeo et al. (2012)
Pancreatic carcinoma, osteosarcoma/chondrosarcoma, soft tissue sarcoma, rectal carcinoma, gastric carcinoma, unknown carcinoma, ovarian carcinoma, malignant melanoma, mesothelioma, bladder carcinoma, hepatocellular carcinoma, and cholangiocarcinoma	800 mg/m²^{^b}	70.8 ± 18.9	N/A	N/A	35.5 ± 8.7 (0–24 h)	Lassen et al. (2010)
	1000 mg/m²^{^b}	127.6 ± 43.5	N/A	N/A	102 ± 58.3 (0–24 h)	Lassen et al. (2010)
Colorectal, melanoma, renal, esophagogastric, breast, cervix, diffuse large B-cell lymphoma, germ cell, lung (non–small cell), mesothelioma, ovary, prostate, pseudomyxoma peritonei, sarcoma, and thymoma	900 mg/m²	145.36 ± 56.20^{^a}	N/A	N/A	47.66 ± 11.78 (0–24 h)^{^a}	Steele et al. (2008)
	1000 mg/m²	100.90 ± 28.67^{^a}	N/A	N/A	31.39 ± 10.47 (0–24 h)^{^a}	Steele et al. (2008)
	1200 mg/m²	168.97 ± 36.04^{^a}	N/A	N/A	60.34 ± 27.93 (0–24 h)^{^a}	Steele et al. (2008)

AUC_(0–t), area under the curve for time 0 to present; N/A, not applicable; T_max, time to plasma C_max.
↵^a Micromolar concentration was calculated based on the provided nanogram per milliliter concentration.
↵^b BEL was administered in combination chemotherapy.